# Laird Superfood, Inc.: financial statements, quarterly

LSF · NYSE · CIK 1650696 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lsf.md) · [Financials](/companies/lsf/financials.md) · [Filings](/companies/lsf/filings.md) · [Insiders](/companies/lsf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lsf/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [9.2](/filings/0001437749-24-033630.md) | [9.2 d](/filings/0001437749-25-005236.md) | [9.9](/filings/0001437749-25-015150.md) | [10.0](/filings/0001437749-25-025135.md) | [11.8](/filings/0001437749-25-034126.md) | [11.6 d](/filings/0001437749-26-010369.md) | [11.7](/filings/0001437749-26-017096.md) | [12.0](/filings/0001437749-26-027697.md) | [12.9](/filings/0001437749-25-034126.md) | [13.3 d](/filings/0001437749-26-010369.md) | [13.9](/filings/0001437749-26-017096.md) | [41.3](/filings/0001437749-26-027697.md) |
| Cost of revenue | $m | [6.3](/filings/0001437749-24-033630.md) | [5.5 d](/filings/0001437749-25-005236.md) | [5.9](/filings/0001437749-25-015150.md) | [5.8](/filings/0001437749-25-025135.md) | [6.7](/filings/0001437749-25-034126.md) | [7.1 d](/filings/0001437749-26-010369.md) | [6.8](/filings/0001437749-26-017096.md) | [7.2](/filings/0001437749-26-027697.md) | [8.2](/filings/0001437749-25-034126.md) | [8.8 d](/filings/0001437749-26-010369.md) | [9.3](/filings/0001437749-26-017096.md) | [28.8](/filings/0001437749-26-027697.md) |
| Gross profit | $m | [2.8](/filings/0001437749-24-033630.md) | [3.7 d](/filings/0001437749-25-005236.md) | [4.0](/filings/0001437749-25-015150.md) | [4.2](/filings/0001437749-25-025135.md) | [5.1](/filings/0001437749-25-034126.md) | [4.5 d](/filings/0001437749-26-010369.md) | [4.9](/filings/0001437749-26-017096.md) | [4.8](/filings/0001437749-26-027697.md) | [4.7](/filings/0001437749-25-034126.md) | [4.5 d](/filings/0001437749-26-010369.md) | [4.6](/filings/0001437749-26-017096.md) | [12.5](/filings/0001437749-26-027697.md) |
| Research and development | $m | [0.0](/filings/0001437749-23-031266.md) | [0.0 d](/filings/0001437749-25-005236.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(2.8)](/filings/0001437749-24-033630.md) | [0.0 d](/filings/0001437749-25-005236.md) | [(1.1)](/filings/0001437749-25-015150.md) | [(0.3)](/filings/0001437749-25-025135.md) | [(0.3)](/filings/0001437749-25-034126.md) | [(0.5) d](/filings/0001437749-26-010369.md) | [(0.2)](/filings/0001437749-26-017096.md) | [(0.4)](/filings/0001437749-26-027697.md) | [(1.0)](/filings/0001437749-25-034126.md) | [(1.8) d](/filings/0001437749-26-010369.md) | [(3.0)](/filings/0001437749-26-017096.md) | [(1.9)](/filings/0001437749-26-027697.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001437749-24-033630.md) | [0.0 d](/filings/0001437749-25-005236.md) | [0.0](/filings/0001437749-25-015150.md) | [0.0](/filings/0001437749-25-025135.md) | [0.0](/filings/0001437749-25-034126.md) | [0.0 d](/filings/0001437749-26-010369.md) | [0.0](/filings/0001437749-26-017096.md) | [0.0](/filings/0001437749-26-027697.md) | [0.0](/filings/0001437749-25-034126.md) | [(0.0) d](/filings/0001437749-26-010369.md) | [(4.7)](/filings/0001437749-26-017096.md) | [(0.0)](/filings/0001437749-26-027697.md) |
| Net income | $m | [(2.7)](/filings/0001437749-24-033630.md) | [0.1 d](/filings/0001437749-25-005236.md) | [(1.0)](/filings/0001437749-25-034126.md) | [(0.2)](/filings/0001437749-25-034126.md) | [(0.2)](/filings/0001437749-25-034126.md) | [(0.4) d](/filings/0001437749-26-010369.md) | [(0.2)](/filings/0001437749-26-027697.md) | [(0.4)](/filings/0001437749-26-027697.md) | [(1.0)](/filings/0001437749-25-034126.md) | [(1.8) d](/filings/0001437749-26-010369.md) | [1.8](/filings/0001437749-26-027697.md) | [(1.8)](/filings/0001437749-26-027697.md) |
| Diluted EPS | $ per share | [(0.28)](/filings/0001437749-23-031266.md) | not reported | not reported | not reported | not reported | not reported | [(0.02)](/filings/0001437749-26-017096.md) | [(0.03)](/filings/0001437749-26-027697.md) | not reported | not reported | [0.11](/filings/0001437749-26-017096.md) | [(0.25)](/filings/0001437749-26-027697.md) |
| Basic EPS | $ per share | [(0.28)](/filings/0001437749-24-033630.md) | not reported | [(0.11)](/filings/0001437749-25-015150.md) | [(0.02)](/filings/0001437749-25-025135.md) | [(0.02)](/filings/0001437749-25-034126.md) | not reported | [(0.02)](/filings/0001437749-26-017096.md) | [(0.03)](/filings/0001437749-26-027697.md) | [(0.09)](/filings/0001437749-25-034126.md) | not reported | [0.12](/filings/0001437749-26-017096.md) | [(0.25)](/filings/0001437749-26-027697.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.1](/filings/0001437749-23-031266.md) | [7.6](/filings/0001437749-25-005236.md) | [7.1](/filings/0001437749-24-015379.md) | [7.6](/filings/0001437749-24-025205.md) | [7.9](/filings/0001437749-24-033630.md) | [8.3](/filings/0001437749-26-010369.md) | [7.0](/filings/0001437749-25-015150.md) | [3.9](/filings/0001437749-25-025135.md) | [5.1](/filings/0001437749-25-034126.md) | [5.1](/filings/0001437749-26-027697.md) | [10.2](/filings/0001437749-26-017096.md) | [23.0](/filings/0001437749-26-027697.md) |
| Current assets | $m | [17.6](/filings/0001437749-23-031266.md) | [16.3](/filings/0001437749-25-005236.md) | [16.1](/filings/0001437749-24-015379.md) | [16.5](/filings/0001437749-24-025205.md) | [17.3](/filings/0001437749-24-033630.md) | [18.0](/filings/0001437749-26-010369.md) | [20.2](/filings/0001437749-25-015150.md) | [19.2](/filings/0001437749-25-025135.md) | [18.4](/filings/0001437749-25-034126.md) | [18.8](/filings/0001437749-26-027697.md) | [37.5](/filings/0001437749-26-017096.md) | [65.3](/filings/0001437749-26-027697.md) |
| Total assets | $m | [19.4](/filings/0001437749-23-031266.md) | [18.0](/filings/0001437749-25-005236.md) | [17.6](/filings/0001437749-24-015379.md) | [18.0](/filings/0001437749-24-025205.md) | [18.8](/filings/0001437749-24-033630.md) | [19.3](/filings/0001437749-26-010369.md) | [21.5](/filings/0001437749-25-015150.md) | [20.4](/filings/0001437749-25-025135.md) | [18.9](/filings/0001437749-25-034126.md) | [19.2](/filings/0001437749-26-027697.md) | [74.9](/filings/0001437749-26-017096.md) | [146](/filings/0001437749-26-027697.md) |
| Current liabilities | $m | [6.1](/filings/0001437749-23-031266.md) | [4.4](/filings/0001437749-25-005236.md) | [4.8](/filings/0001437749-24-015379.md) | [5.3](/filings/0001437749-24-025205.md) | [5.5](/filings/0001437749-24-033630.md) | [5.9](/filings/0001437749-26-010369.md) | [8.0](/filings/0001437749-25-015150.md) | [7.0](/filings/0001437749-25-025135.md) | [6.0](/filings/0001437749-25-034126.md) | [7.7](/filings/0001437749-26-027697.md) | [11.7](/filings/0001437749-26-017096.md) | [21.5](/filings/0001437749-26-027697.md) |
| Total liabilities | $m | [6.4](/filings/0001437749-23-031266.md) | [4.6](/filings/0001437749-25-005236.md) | [5.0](/filings/0001437749-24-015379.md) | [5.4](/filings/0001437749-24-025205.md) | [5.7](/filings/0001437749-24-033630.md) | [6.1](/filings/0001437749-26-010369.md) | [8.2](/filings/0001437749-25-015150.md) | [7.1](/filings/0001437749-25-025135.md) | [6.0](/filings/0001437749-25-034126.md) | [7.8](/filings/0001437749-26-027697.md) | [12.0](/filings/0001437749-26-017096.md) | [24.4](/filings/0001437749-26-027697.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [13.0](/filings/0001437749-24-033630.md) | [13.4](/filings/0001437749-26-010369.md) | [12.7](/filings/0001437749-25-034126.md) | [12.6](/filings/0001437749-25-034126.md) | [13.1](/filings/0001437749-25-034126.md) | [13.2](/filings/0001437749-26-027697.md) | [13.3](/filings/0001437749-26-027697.md) | [13.4](/filings/0001437749-26-027697.md) | [12.8](/filings/0001437749-25-034126.md) | [11.5](/filings/0001437749-26-027697.md) | [13.5](/filings/0001437749-26-027697.md) | [11.0](/filings/0001437749-26-027697.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,469) d](/filings/0001437749-24-033630.md) | [163 d](/filings/0001437749-25-005236.md) | [(422)](/filings/0001437749-25-015150.md) | [643 d](/filings/0001437749-25-025135.md) | [306 d](/filings/0001437749-25-034126.md) | [339 d](/filings/0001437749-26-010369.md) | [(1,275)](/filings/0001437749-26-017096.md) | [(2,828) d](/filings/0001437749-26-027697.md) | [1,249 d](/filings/0001437749-25-034126.md) | [68.4 d](/filings/0001437749-26-010369.md) | [(3,833)](/filings/0001437749-26-017096.md) | [1,451 d](/filings/0001437749-26-027697.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | [72.2](/filings/0001437749-26-017096.md) | [8.4 d](/filings/0001437749-26-027697.md) | not reported | not reported | [3.9](/filings/0001437749-26-017096.md) | [42.2 d](/filings/0001437749-26-027697.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2021 (2021-09-30) | Q4 FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.0](/filings/0000950170-23-008473.md) | [9.1](/filings/0000950170-23-008473.md) | [9.1](/filings/0000950170-23-021202.md) | [9.1](/filings/0000950170-23-041270.md) | [9.2](/filings/0000950170-23-008473.md) | [9.2](/filings/0000950170-23-008473.md) | [9.2](/filings/0000950170-23-021202.md) | [9.3](/filings/0000950170-23-041270.md) | [10.3](/filings/0001437749-26-017096.md) | [10.5](/filings/0001437749-26-027697.md) | [11.6](/filings/0001437749-26-017096.md) | [11.0](/filings/0001437749-26-027697.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 11,192,884 at 2026-08-10, from the cover of the [10-Q filed 2026-08-13](/filings/0001437749-26-027697.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.